Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA13 Leflunomide
D00749 Leflunomide (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Antimetabolites, Antiproliferative
Leflunomide
D00749 Leflunomide (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D00749 Leflunomide (JAN/USP/INN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D00749 Leflunomide
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00749 Leflunomide
Metabolizing enzyme inhibitor
DG01643 CYP2C9 inhibitor
D00749 Leflunomide
Drug classes [BR:br08332]
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D00749 Leflunomide
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
DHODH
D00749 Leflunomide (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00749
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00749
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00749
